Rheumatoid Arthritis

Precision medicine in rheumatoid arthritis expanded in a small but key measure late last year, when Quest Diagnostics and Scipher Medicine announced a partnership to provide RNA extraction and sequencing services for the latter’s PrismRA test.

Individuals with higher cereal fiber intake are less likely to develop rheumatoid arthritis, according to data published in Nature Scientific Reports.

The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.

Patients with rheumatoid arthritis — either seropositive or seronegative — demonstrate a 1.66-fold higher risk for depression vs. healthy controls, according to data published in JAMA Network Open.

Data from a cross-sectional study showed that U.S. adults who reported cannabis use had a higher risk for coronary heart disease, MI and stroke compared with nonusers.

Six biomarkers were associated with baseline and treatment-associated changes in arterial inflammation in patients with rheumatoid arthritis and could be used to predict CVD risk in that population, researchers reported.

The FDA has approved Simlandi as the third interchangeable biosimilar to Humira following a rejection in April 2023 stemming from issues at the developer’s manufacturing facility.

I am thrilled to introduce our cover story this month, “‘Exploring the Power of Their Mind’: Data May Offer Clues to Harnessing the Placebo Effect,” to the readers of Healio Rheumatology. I say this for several reasons.

SCOTTSDALE, Ariz. — The Wnt signaling pathway, neutrophil extracellular traps and PRIME cells represent “extremely important” emerging targets in rheumatoid arthritis, according to a speaker here.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.